Metropolitan Life Insurance CO Glycomimetics Inc Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $32,894 - $150,961	-11,748 Closed	0 $0
Q2 2019 Jul 12, 2023	BUY	$10.6 - $13.12 $124,528 - $154,133	11,748 New	11,748 $140,000
Q1 2019 Jul 13, 2023	BUY	$9.96 - $13.44 $117,010 - $157,893	11,748 New	11,748 $146,000
Q1 2019 Mar 30, 2023	BUY	$9.96 - $13.44 $117,010 - $157,893	11,748 New	11,748 $146,000
Q1 2019 May 16, 2019	BUY	$9.96 - $13.44 $53,963 - $72,817	5,418 Added 85.59%	11,748 $146,000
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $53,963 - $72,817	-5,418 Reduced 46.12%	6,330 $101,000
Q4 2018 Jul 13, 2023	BUY	$8.47 - $14.71 $99,505 - $172,813	11,748 New	11,748 $111,000
Q4 2018 Feb 14, 2019	BUY	$8.47 - $14.71 $77,712 - $134,964	9,175 Added 356.59%	11,748 $111,000
Q3 2018 Jul 13, 2023	BUY	$13.7 - $17.12 $160,947 - $201,125	11,748 New	11,748 $169 Million
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $125,697 - $157,076	-9,175 Reduced 78.1%	2,573 $37,000
Q2 2018 Aug 15, 2018	BUY	$14.63 - $19.19 $171,873 - $225,444	11,748 New	11,748 $0

28.9M

51K

1.4K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.